Renal transplant
RecruitingSafety of Two Doses of Siplizumab Compared with Rabbit Anti‑Human Thymocyte Immunoglobulin in Kidney Transplant Recipients Receiving Standard Immunosuppression
Safety of Two Doses of Siplizumab Compared with Rabbit Anti‑Human Thymocyte Immunoglobulin in Kidney Transplant Recipients Receiving Standard Immunosuppression
- Disease:Renal transplant
- Substances:SiplizumabRabbit Anti-Human Thymocyte Immunoglobulin
Spain- Participants:18–64 years · 65+ years
- Substances:Siplizumab
- Sponsor:Itb-Med LLC














